Yongqing Li1, Ting Zhao, Baoling Liu, Ihab Halaweish, Ralph Mazitschek, Xiuzhen Duan, Hasan B Alam. 1. From the General Surgery (Y.L., T.Z., B.L., I.H., H.B.A.), Department of Surgery, University of Michigan Hospital, Ann Arbor, Michigan; Center for Systems Biology (R.M.), Massachusetts General Hospital, Boston; and Chemical Biology Program (R.M.), the Broad Institute of Harvard and MIT, Cambridge, Massachusetts; and Department of Pathology (X.D.), Loyola University Medical Center, Maywood, Illinois.
Abstract
BACKGROUND: We recently demonstrated that suberoylanilide hydroxamic acid, a broad-spectrum histone deacetylase (HDAC) inhibitor that inhibits HDACs 1, 2, 3, and 6, improves survival in a mouse model of cecal ligation and puncture (CLP)-induced lethal sepsis. The current study was undertaken to determine the effect of selective inhibition of HDAC isoform on survival, key cytokine production, organ injury, bacteria clearance, and cell apoptosis. METHODS: In Experiment 1, C57BL/6J mice were subjected to CLP and, 1 hour later, given intraperitoneal injections of (1) Tubastatin A (inhibitor of HDAC6) dissolved in dimethyl sulfoxide (DMSO), (2) MS-275 (inhibitor of HDACs 1, 2, and 3) in DMSO, and (3) DMSO only. Survival was monitored for 10 days. In Experiment 2, 1 hour after CLP, animals were treated with DMSO vehicle or Tubastatin A. Sham-operated animals served as control. Peritoneal fluid and blood samples were collected for measurement of cytokines at 24 hours or 48 hours. Blood at 48 hours was also used to determine bacteria load. Liver was harvested to evaluate acute liver injury. In Experiment 3, Primary splenocytes were used to assess cytokine responses and phagocytosis. Macrophages were cultured and harvested 3 hours and 6 hours after lipopolysaccharide stimulation in the absence or presence of Tubastatin A to analyze cell apoptosis. RESULTS: Animals treated with Tubastatin A, but not MS-275, displayed a significant improvement in survival. Moreover, Tubastatin A significantly inhibited cytokine production in peritoneal fluid and plasma as well as in supernatant from splenocytes stimulated with lipopolysaccharide. Tubastatin A significantly attenuated acute liver injury, increased blood bacteria clearance and splenocyte phagocytosis, and decreased macrophage apoptosis. CONCLUSION: HDAC6 inhibition significantly improves survival, reduces "cytokine storm," attenuates acute livery injury, increases bacteria clearance and immune cell phagocytosis, and inhibits macrophage apoptosis in a lethal mouse CLP model.
BACKGROUND: We recently demonstrated that suberoylanilide hydroxamic acid, a broad-spectrum histone deacetylase (HDAC) inhibitor that inhibits HDACs 1, 2, 3, and 6, improves survival in a mouse model of cecal ligation and puncture (CLP)-induced lethal sepsis. The current study was undertaken to determine the effect of selective inhibition of HDAC isoform on survival, key cytokine production, organ injury, bacteria clearance, and cell apoptosis. METHODS: In Experiment 1, C57BL/6J mice were subjected to CLP and, 1 hour later, given intraperitoneal injections of (1) Tubastatin A (inhibitor of HDAC6) dissolved in dimethyl sulfoxide (DMSO), (2) MS-275 (inhibitor of HDACs 1, 2, and 3) in DMSO, and (3) DMSO only. Survival was monitored for 10 days. In Experiment 2, 1 hour after CLP, animals were treated with DMSO vehicle or Tubastatin A. Sham-operated animals served as control. Peritoneal fluid and blood samples were collected for measurement of cytokines at 24 hours or 48 hours. Blood at 48 hours was also used to determine bacteria load. Liver was harvested to evaluate acute liver injury. In Experiment 3, Primary splenocytes were used to assess cytokine responses and phagocytosis. Macrophages were cultured and harvested 3 hours and 6 hours after lipopolysaccharide stimulation in the absence or presence of Tubastatin A to analyze cell apoptosis. RESULTS: Animals treated with Tubastatin A, but not MS-275, displayed a significant improvement in survival. Moreover, Tubastatin A significantly inhibited cytokine production in peritoneal fluid and plasma as well as in supernatant from splenocytes stimulated with lipopolysaccharide. Tubastatin A significantly attenuated acute liver injury, increased blood bacteria clearance and splenocyte phagocytosis, and decreased macrophage apoptosis. CONCLUSION:HDAC6 inhibition significantly improves survival, reduces "cytokine storm," attenuates acute livery injury, increases bacteria clearance and immune cell phagocytosis, and inhibits macrophage apoptosis in a lethal mouseCLP model.
Authors: Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson Journal: Cell Date: 2003-03-07 Impact factor: 41.582
Authors: Ting Zhao; Yongqing Li; Baoling Liu; Zhengcai Liu; Wei Chong; Xiuzhen Duan; Danielle K Deperalta; George C Velmahos; Hasan B Alam Journal: Surgery Date: 2013-08 Impact factor: 3.982
Authors: Kyle V Butler; Jay Kalin; Camille Brochier; Guilio Vistoli; Brett Langley; Alan P Kozikowski Journal: J Am Chem Soc Date: 2010-08-11 Impact factor: 15.419
Authors: Ludmila V Deriy; Erwin A Gomez; Guangping Zhang; Daniel W Beacham; Jessika A Hopson; Alexander J Gallan; Pavel D Shevchenko; Vytautas P Bindokas; Deborah J Nelson Journal: J Biol Chem Date: 2009-12-18 Impact factor: 5.157
Authors: Wei Chong; Yongqing Li; Baoling Liu; Ting Zhao; Eugene Y Fukudome; Zhengcai Liu; William M Smith; George C Velmahos; Marc A deMoya; Hasan B Alam Journal: J Surg Res Date: 2012-07-26 Impact factor: 2.192
Authors: Panpan Chang; Michael Weykamp; Isabel S Dennahy; Aaron M Williams; Umar F Bhatti; Baoling Liu; Vahagn C Nikolian; Yongqing Li; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2018-05 Impact factor: 3.313
Authors: Juliana K Ariffin; Kaustav das Gupta; Ronan Kapetanovic; Abishek Iyer; Robert C Reid; David P Fairlie; Matthew J Sweet Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: Simone E Dekker; Vahagn C Nikolian; Martin Sillesen; Ted Bambakidis; Patrick Schober; Hasan B Alam Journal: J Neurosci Res Date: 2017-07-25 Impact factor: 4.164
Authors: Aaron M Williams; Isabel S Dennahy; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Yongqing Li; Hasan B Alam Journal: Shock Date: 2019-09 Impact factor: 3.454